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Dent’s disease (MIM #300009) is a rare X-linked disorder characterized by various degrees of 
proximal tubular (PT) dysfunction, nephrocalcinosis and nephrolithiasis. The exact 
prevalence is unknown. The disease was first reported by Dent and Friedman, who 
described two males with vitamin D resistant rickets, hypercalciuria and low molecular 
weight proteinuria (LMWP) (Dent & Friedman, 1964). Based on these data and another 13 
patients with a similar phenotype, Wrong et al. coined the term “Dent’s disease” for the 
combination of X-linked low molecular weight proteinuria, hypercalciuria, 
nephrocalcinosis, metabolic bone disease and progressive renal failure (Wrong et al., 1994). 
With the advent of molecular genetics it has become clear that the phenotypically similar 
disorders X-linked recessive nephrolithiasis with renal failure (MIM #310468) and X-linked 
recessive hypophosphatemic rickets (MIM #300554) are also due to mutations in the CLCN5  
gene (Lloyd et al., 1996). Familial idiopathic LMW proteinuria with hypercalciuria in 
Japanese patients (MIM #308990) – also referred to as Dent’s Japan disease (Igarashi et al., 
1995) - is a fourth clinical entity resulting from CLCN5 mutations (Nakazato et al., 1997). 
Therefore, Scheinman proposed to summarize CLCN5-associated renal disease under the 
term “X-linked hypercalciuric nephrolithiasis” (Scheinman, 1998). The same clinical 
phenotype has been observed with some mutations in the oculo-cerebrorenal syndrome of 
Lowe (OCRL) gene and is referred to as Dent-2 disease (MIM #300555) (Hoopes et al., 2005; 
Utsch et al., 2006).  
2. Clinical manifestations 
The clinical presentation of Dent’s disease is frequently subtle with the majority of patients 
being asymptomatic during childhood. Therefore, many patients are identified through 
urine screening for hematuria and proteinuria as it is done systematically in Japanese school 
children (Lloyd et al., 1997).  
A summary and the frequency of the major clinical and biochemical characteristics of Dent’s 
disease are presented in table 1. Hereby it should be noted that the manifestations of Dent’s 
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disease are highly variable even within the same family and there is no genotype-phenotype 





















































Table 1. Spectrum of renal dysfunction in Dent’s disease due to CLCN5 (Dent 1) and OCRL  
(Dent 2) mutations (adapted from Bökenkamp et al., 2009).  
Although nephrocalcinosis and hypercalciuria are characteristic findings in Dent’s disease, it 
is the presence of LMWP, which distinguishes patients with CLCN5 mutations from other 
hypercalciuric stone-formers (Scheinman et al., 2000). Protein excretion in Dent’s disease is 
around 0.5 to 1 g per day, with LMWP accounting for 50 to 70% of the total protein 
(Scheinman et al., 1998).  LMWP can be detected by means of SDS-PAGE urine 
electrophoresis, or by measurement of marker proteins such as alpha-1 microglobulin, beta-
2-microglobulin, cystatin C, lysozyme or retinol-binding protein in the urine. As albumin 
absorption by endocytosis in the proximal tubule is also impaired, albuminuria is present as 
well and can be detected by urine dipstick analysis. Recently, two papers reported 
asymptomatic nephrotic-range proteinuria of up to 50 mg/m2/h in 6 patients with CLCN5 
mutations (Frishberg et al., 2009; Copelovitch et al., 2007). Of note, serum albumin was 
normal in all these patients and urine protein consisted largely of low molecular proteins, 
which underscores the need to measure low molecular proteins in patients with 
unexplained proteinuria. 
The majority of patients have nephrocalcinosis, while nephrolithiasis is observed in some 
40% of patients (Claverie-Martin et al., 2011). The kidney stones are composed of calcium 
phosphate, calcium oxalate or a combination of both (Wrong et al., 1994; Scheinman, 1998). 
Nephrolithiasis and nephrocalcinosis are also observed in the absence of hypercalciuria 
(Ludwig et al., 2006), which may be explained by a defect in the clearance of microcrystals in 






2003, 2004).  Urinary excretion of citrate and oxalate is normal in the majority of cases 
(Wrong et al., 1994; Scheinman et al., 1998), while urinary acidification may become 
impaired with progressive nephrocalcinosis (Ludwig et al., 2006).   
Mild to moderate hypercalciuria of 4 to 6 mg/kg per day is characteristic for Dent’s disease, 
with higher calcium excretion being found in childhood (Scheinman, 1998). In about 10% of 
patients with CLCN5 mutations, hypercalciuria is missing, in particular in patients with renal 
failure because calcium excretion diminishes with decreasing GFR (Ludwig et al., 2006). Half 
of the patients are reported to have fasting hypercalciuria and almost all have an exaggerated 
calciuric response after an oral calcium load (Reinhart et al., 1995). Serum parathyroid 
hormone levels are usually low, while levels of 1,25-dihydroxyvitamin D are frequently high 
(Scheinman, 1998). This reflects the complex balance between the loss of 25-hydroxyvitamin D 
along with vitamin D binding protein and the stimulation of 1,25-dihydroxyvitamin D 
synthesis by increased luminal parathyroid hormone delivery (Günther et al., 2003).   
Kidney function is normal during childhood in most patients with a slowly progressive 
decline during adulthood leading to end-stage renal failure in 30 to 80% of affected patients 
in the 3rd to 5th decade (Wrong et al., 1994; Bökenkamp et al., 2009).  Histological studies 
may be normal or show tubular atrophy and interstitial fibrosis, foci of calcinosis and non-
specific glomerular changes as hyalinosis, sclerosis and periglomerular fibrosis (Wrong et 
al., 1994). Recently, two papers reported focal segmental glomerulosclerosis with 
asymptomatic nephrotic range proteinuria associated with CLCN5 mutations (Frishberg et 
al., 2009; Copelovitch et al., 2007). As pointed out by Wrong et al., the progressive decline in 
renal function is more severe than would be expected as a result of nephrocalcinosis alone 
(Wrong et al., 1994), but is characteristic for various forms of the renal Fanconi syndrome 
(Norden et al., 2001). Norden et al. demonstrated increased concentrations of potentially 
bioactive hormones and chemokines such as parathyroid hormone, insulin, insulin-like 
growth factor 3, growth hormone and monocyte chemoattractant protein 1 in the urine of 
patients with Dent’s disease, autosomal dominant Fanconi syndrome and Lowe syndrome 
which may be involved in the pathogenesis of the progressive tubulointerstitial damage 
(Norden et al., 2001).  
The proximal-tubular defect in Dent’s disease may lead to hypophosphatemia. However, 
there is no clear correlation between the degree of hypophosphatemia and the presence of 
rickets, which can be observed in about 1/3 of Dent’s patients (Scheinman, 1998). Renal 
potassium wasting – although relatively infrequent - may be exacerbated by the use of 
thiazide diuretics as reported by Blanchard et al. (Blanchard et al., 2008).  Another finding in 
patients with Dent’s disease as well as in other conditions with proximal tubular 
dysfunction is the decreased uptake of 99mcTc-DMSA (dimercaptosuccinic acid) in renal 
parenchyma with rapid excretion of the tracer into the urine (Lee et al., 2009).  
Depending on the degree of lionization, female carriers display a milder phenotype. LMWP is 
seen in 60 to 90%, while hypercalciuria was observed in around 30% (Reinhart et al., 1995). 
Although abnormal, the amount of LMWP is 10 to 100 times lower than in males (Scheinman, 
1998). Nephrolithiasis and nephrocalcinosis are infrequently seen, and there is only 1 case of 
end stage renal disease in a female carrier reported so far (Devuyst & Thakker, 2010).  
The diagnosis of Dent’s disease is based on the presence of low molecular weight proteinuria, 
hypercalciuria, nephrocalcinosis/nephrolithiasis and various degrees of generalized 
proximal dysfunction and decreased GFR in otherwise phenotypically healthy males.  
Differential diagnosis should include other inherited and acquired causes of proximal tubular 
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3. Underlying genetic causes 
3.1 CLCN5 gene (Dent 1, MIM #300008) 
The CLCN5 gene, affected in patients with Dent 1 disease, was initially identified in a family 
with a microdeletion on the X-chromosome (Fisher et al., 1995). The inheritance is X-linked 
with ~10% of the mutations being de novo (Devuyst & Thakker, 2010). CLCN5 encodes an 
electrogenic Cl-/H+ antiporter (ClC-5) (Picollo & Pusch, 2005; Scheel et al., 2005) with a 
transport stoichiometry of 2 Cl- / 1 H+ (Zifarelli & Pusch 2009). ClC-5 contains two 
phosphorylation and one N-glycosylation sites and comprises 18 helices (A - R), which show 
an internally repeated pattern (helices B - I and J - Q, respectively) forming two roughly 
repeated halves that span the membrane in opposite (antiparallel) orientations (Dutzler et 
al., 2002) (Fig.1). The selective flow of chloride ions across cell membranes is catalyzed by a 
ClC-5 homodimer, with each channel subunit forming its own chloride pore (Dutzler et al., 
2002; Jentsch, 2002). 
 
 
Fig. 1. Topology diagram of the ClC-5 protein adopted from Dutzler et al. (2002, 2003) and 
Wu et al. (2003). Boxed areas depict helices A-R with the extracellular region shown above, 
and the cytoplasmic region shown below. Amino acids (helices D, F, N, and R) involved in 
chloride selectivity filter formation are indicated by black triangles; helices H, I, P, and Q are 
involved in formation of the dimer interface. Further regions of functional significance are 
boxed in light gray: SSS, sorting signal sequence (Schwappach et al., 1998); CBS1 and CBS2, 
cystathionine-┚-synthase sequences forming the so-called Bateman domain (Bateman, 1997) 
that binds ATP (Scott et al., 2004); PY, proline/tyrosine-like internalization signal motif 
(Schwake et al., 2001). The additional 70 aminoterminal residues in the enlarged ClC-5 
isoform (Ludwig et al., 2003) are shown with overall numbering starting with the 
methionine of the short variant (from Ludwig et al., 2005 printed with kind permission of 






The CLCN5 gene spans ~170 kb on chromosome Xp11.23/p11.22 and comprises 17 exons 
with transcription initiating from at least four different start sites. Transcripts including the 
untranslated exon 1a (Hayama et al., 2000) or 1b (Fisher et al., 1995) are spliced to exon 2 
containing the start-ATG, whereas a third mRNA comprises a larger exon 1b and retains 
intron 1 (Forino et al., 2004). Two further transcripts (harbouring additional exons I-IV), 
arise due to alternative splicing of exon II, and are also spliced to exon 2 (Ludwig et al., 
2003). Both transcripts carry the start-ATG in exon III, thereby coding for a longer isoform of 
the ClC-5 protein with additional 70 amino acids at the intracellular amino terminus. Since 
these two mRNAs maintain the reading frame, the start-codon of the shorter form (746 
amino acids) here resides at position 71. So far, the longer variant has only been detected at 
mRNA but not at protein level (Ludwig et al., 2003). 
More than 140 distinct CLCN5 mutations, distributed along the entire gene, have been 
reported in patients with Dent 1 disease and no major mutational hot spots have been 
observed (Wu et al., 2009). There is also no evidence for a genotype-phenotype correlation. 
Various mutations were found to be associated with quite different clinical phenotypes 
ranging from ‘classic’ Dent 1 disease to very slight urinary abnormalities, not only in 
unrelated patients, but even within the same family (Ludwig et al., 2006).  
Dysfunction of mutant ClC-5 channels may be caused by various mechanisms and a lot of 
the mutations observed are predicted to result in a truncated or absent protein. Complete 
loss of antiporter function might be caused by impaired homodimerization, altered current 
kinetics, altered ion selectivity, or defective intracellular trafficking. Heterologous 
expression of various CLCN5 mutants, in either Xenopus laevis oocytes or HEK293 cells, 
determined a loss of Cl- conductance in the majority of mutations tested (Lloyd et al., 1996; 
Ludwig et al., 2005). Further consequences of CLCN5 mutations were (i) improper N-
glycosylation with endoplasmic reticulum retention and degradation of ClC-5 (ii) defective 
endosomal acidification, (iii) altered endosomal distribution of ClC-5 but not defective 
endosomal acidification (IV) delayed processing with reduced stability and lower cell 
surface expression, or impaired internalization (Ludwig et al., 2005; Smith et al., 2009; Grand 
et al., 2011). The majority of missense mutations cluster at the dimer interface and have been 
shown to disrupt the assembly of the homodimers (Wu et al., 2003; Smith et al., 2009).  
ClC-5-deficient mice recapitulate the human phenotype of Dent’s disease with LMWP, 
generalized aminoaciduria, glycosuria, hypercalciuria and renal calcium deposits. Proximal 
tubular endocytosis is severely impaired in ClC-5-deficient mice, proving a role for ClC-5 in 
endosomal uptake of low molecular weight proteins (Wang et al., 2000).  
3.2 OCRL gene (Dent 2, MIM #300555) 
Recent investigations have revealed defects in the OCRL gene in about 15% of patients with 
a Dent’s phenotype (Hoopes et al., 2005; Böckenhauer et al., 2011). This gene, located at 
Xq26.1 comprises 24 exons occupying 52 kb, and alternative splicing of exon 18a enlarges 
the resultant 893 amino acids-long protein by eight (in frame) additional amino acids 
(Nussbaum et al., 1997). OCRL encodes a phospatidylinositol 4,5-bisphosphate 5-
phosphatase and mutations herein were initially found to cause Lowe syndrome (MIM 
#309000), a pleiotropic disease, characterized by the triad of congenital cataracts, mental 
retardation and incomplete renal Fanconi syndrome (Böckenhauer et al., 2008). In the OMIM 
database, Dent’s disease associated with OCRL mutations is now termed Dent 2 disease 
(MIM #300555) to distinguish these patients from the more severe Lowe phenotype. Except 
a lower prevalence of nephrocalcinosis, the renal phenotype is comparable to Dent 1 cases 
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harbouring a CLCN5 mutation (Table 1). Dent 2 may present with (mild) extra-renal Lowe 
symptoms (peripheral cataracts, stunted growth, mild retardation, elevation of serum 
CK/LDH), implying that Dent 2 disease actually represents a mild form of Lowe syndrome 
(Bökenkamp et al., 2009; Böckenhauer et al., 2011). 
By now, 44 Dent 2 patients having OCRL mutations have been reported (Böckenhauer et al., 
2011; Hichri et al., 2011). Whereas frame shift mutations or splice defects leading to a 
premature stop codon in Dent 2 patients all cluster in exons 1-7, they exclusively affect 
exons 8-23 in Lowe syndrome. Dent 2 was also observed with several missense mutations in 
exons 9-19, exons typically implicated in Lowe syndrome. Initially, none of the mutations 
observed in Dent 2 cases had been found in association with classic Lowe syndrome and 
there was no explanation why the phenotypic consequences of premature termination 
mutations, expected to cause classic Lowe syndrome, led to the milder form of Dent 2. Most 
recently, however, Hichri et al. (2011) reported two different OCRL mutations (p.Ile274Thr, 
p.Arg318Cys) each causing both phenotypes even in the same family. Moreover, a patient 
showing the complete phenotypic Lowe spectrum but absence of any ocular involvement 
harboured an exon 8 termination mutation (p.Gln199X) (Ludwig et al., 2011), thereby 
presenting the most severe clinical intermediate between Dent disease and Lowe syndrome. 
Given these observations, there exists a phenotypic continuum between patients with Dent 2 
disease and Lowe syndrome, not only between patients harbouring different OCRL 
mutations but also between family members affected by the same OCRL defect. 
Nonetheless, the reason(s) why different OCRL mutations manifest with the respective 
phenotype remain(s) to be elucidated. This may be related to the expression profile of 
inositol polyphosphate 5-phosphatase (INPP5B), which has been shown to compensate for 
Ocrl deficiency in a mouse model (Jänne et al., 1998). Mice deficient in Ocrl or Inpp5b show 
little or no phenotype, whereas deficiency of both genes leads to death before implantation. 
Interestingly, mouse Inpp5b and human INPP5B differ in expression and splice-site choice 
(Bothwell et al., 2010). Most recently a mouse model for Lowe syndrome and Dent 2 disease 
tubulopathy was established by expressing human INPP5B in the Ocrl-/- mice (Bothwell et 
al., 2011). These mice showed reduced postnatal growth, LMWP, and aminoaciduria and 
suggest that human INPP5B genotype may influence the clinical manifestation of Dent 
2/Lowe syndrome.  
It has also been speculated that the use of alternative initiation codons (methionine at 
position 158, 187, and 206) in exons 7 and 8 will allow the synthesis of truncated OCRL 
proteins. Indeed, Hichri et al. (2011) have detected two smaller proteins (around 80 kDa) 
instead of the 104 kDa full-length protein in a Dent 2 case lacking the normal initiator ATG 
in exon 1. Hence, some residual activity of these smaller products might contribute to the 
phenotypic differences observed.  
3.3 Dent’s disease and other candidate genes 
Molecular analyses provided evidence for genetic heterogeneity in Dent’s disease as in 
around 25% of patients with typical features of Dent’s disease no CLCN5 or OCRL mutations 
could be detected (Böckenhauer et al., 2011). These patients may carry a CLCN5/OCRL 
mutation undetectable by the common PCR analysis (e.g. in the promoter or an intron, 
thereby leading to a decrease in expression or a cryptic splice product). On the other hand, a 
defect in another gene phenocopying Dent’s disease might be responsible. Four candidate 






CLCN4, the gene encoding ClC-4 has been analyzed (Ludwig and Utsch, 2004; Hoopes et al. 
2005; Wu et al., 2009), since it is located on Xp22.3 and mutations herein would consequently 
show an X-linked mode of inheritance. ClC-4 (i) is also a member of the ClC-family of 
chloride channels, giving rise to strongly outwardly rectifying anion currents closely 
resembling those of ClC-5 (Friedrich et al., 1999), (ii) alike ClC-5, contributes to endosomal 
acidification and trafficking by epithelial cells of the renal proximal tubule (Mohammad-
Panah et al., 2003), and (iii) could be co-immunoprecipitated with ClC-5, indicating that 
both channels may interact in vivo (Mohammad-Panah et al., 2003). In a total of 30 unrelated 
cases no defect was observed. 
Hoopes et al. (2005) investigated the SLC9A6 gene in a panel of 13 patients that met the strict 
criteria for Dent's disease. SLC9A6, located at Xq26.3, encodes the Na+/H+ exchanger 6 
(NHE6; Numata et al., 1998). This sodium-proton exchanger localizes to early recycling 
endosomes and may contribute to the maintenance of the unique acidic pH values of Golgi 
and post-Golgi compartments (Nakamura et al., 2005). The X-linked TMEM27 gene has also 
been suggested a good candidate since it codes for collectrin, a transmembrane glycoprotein 
expressed on the apical membrane of proximal tubuli that was shown to be essential for 
renal amino acid transport (Danilczyk et al., 2006). However, mutation analysis was 
negative in 26 Dent-like patients as well (Tosetto et al., 2009) as was the case in 10 patients 
analyzed for defects in CFL1 (Wu et al., 2009). This autosomal gene locates on chromosome 
11q13.1 and encodes cofilin, a protein shown to interact with ClC-5 in regulating albumin 
uptake in the proximal tubule (Hryciw et al., 2003). 
Given these negative results, a further causative gene still awaits identification. Moreover, 
effects of (a) modifier locus(i) may influence the phenotype in Dent’s patients. This would 
explain the heterogeneity in the clinical features observed among non-related patients 
sharing the same mutation or even between family members affected by the same defect 
(Ludwig et al., 2006). 
4. Pathophysiology of Dent’s disease 
4.1 Localisation of ClC-5 in the kidney 
In the kidney ClC-5 is found predominantly expressed in the proximal tubule and in ┙-
intercalated cells of the distal nephron. A small fraction may be present at the cell surface of 
the medullary thick ascending limb of Henle’s loop. In the proximal tubule ClC-5 is mainly 
located in the intracellular subapical endosomes, where it is co-expressed with the proton 
pump (V-type H+ ATPase).  
4.2 Role of ClC-5 in endosomal acidification 
Along the endocytic pathway a successively decreasing pH from 6.3 to 4.7 is detected in 
early endosomes, late endosomes and lysosomes with a change in the ionic composition 
along the endocytic pathway (Casey et al., 2010; Scott et al., 2010). The acidification is mainly 
due to vacuolar H+ ATPase, mediating ATP-dependent transport of protons. The movement 
of H+ across the endosomal membrane results in a net charge translocation, which has to be 
neutralized by a passive influx of counter ions such as chloride or by efflux of another 
cation. Na+ entry increases the membrane potential and limits acidification.  
TRPML3 belongs to the mucolipin family of the TRP ion channels and is present in the early 
endosomes (Puertollano et al., 2009). Shortly after internalisation of the endosomes there is 
rapid release of Ca2+ from early endosomes through TRPML3 that is necessary for allowing 
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acidification of this compartment. Once late endosomes or lysosomes become highly acidic, 
the low pH inhibits TRPML3 channel activity, stopping Ca2+ exit and preventing further 
acidification (Martina et al., 2009; Lelouvier et al., 2010) (Fig.2). 
In a study in isolated endosomes performed by Saito et al. (2007) the presence of two poor 
channels (TPC), releasing Ca2+ from the endosome, was demonstrated. Ca2+ release was 
inhibited by the endosome luminal Cl- with a K50 of 82 mM. Reduction of Cl- activated Ca2+ 
release, which in turn stimulates H+ transport to the lumen (Fig.2).  
There is ample evidence that ClC-5 has an essential role in the acidification of the 
endosomes (Plans et al., 2009; Wellhouser et al., 2010; Smith & Lippiat, 2010).  Two research 
groups demonstrated that ClC-5 functions as a voltage–dependent electrogenic 
chloride/proton exchanger (Picollo et al., 2005; Scheel et al., 2005). In their studies the 
currents required 20-40 mV voltages, which are not observed in vivo. When transposed to 
endosomal membranes, it means a movement of a positive charge (H+) into and of negative 
charge (Cl-) out of the endosome.  Sonawane et al. (2009) showed that within 60 s Cl- 
concentration in the lumen is decreased from 120 to 20-30 mmol. Zifarelli and Pusch (2009) 
determined the absolute proton fluxes using Xenopus oocytes from the extracellular proton 
gradient using a pH sensitive dye. A transport stochiometry of 2Cl-/1H+ was demonstrated. 
Smith and Lippiat (2010) demonstrated using a targeted pH sensitive fluorescent protein in 
opossum proximal tubular cells that endosomal acidification was only partially sensitive to 
the inhibitor of V-ATPase bafilomycin–A1. In the presence of bafilomycin-A1, the 
acidification was almost fully ablated by the knockdown of endogenous ClC-5 by siRNA. 
Contrasting previous assumption, these authors suggested that ClC-5 exchanges two Cl- 
ions from the endosomal lumen for a proton from the cytoplasm. This leads to endosomal 
acidification directly by ClC-5 in parallel with V-ATPase (Fig.2).  
 
 
V-ATPase; vacuolar ATPase. ClC-5; chloride channel 5 mutated in Dent 1 disease. NHE6; Na+/H+ 
exchanger 6. TRPML3; mucolipin 3. TPC; two poor channel.  
Fig. 2. Major classes of transporters in the early endosome; protons can enter endosome via 
V-ATPase, ClC-5 and NHE6. Ca 2+ exit via TRPM3 and via TPC counteracting net charge 
translocation facilitating endosomal acidification.  Na+ entry increases endosomal 






4.3 Role of decreased endosomal acidification in the disturbed proximal tubule 
transport 
A remarkable study was performed by Novarino et al. (2010). They generated mice with a 
mutation that converted ClC-5 exchanger into a pure Cl- conductor. In these conditions 
ATP-dependent acidification of renal endosomes was normal however, proximal tubular 
endocytosis was impaired. Because the mutation was introduced into the 
intramembraneous part of the protein, this study made it unlikely that a disturbed 
interaction between ClC-5 and other partners is involved in the pathogenesis of Dent’s 
disease (Reed et al., 2010). The impaired reabsorption in the proximal tubule is still 
presumably due to the failure to recycle specific transporters, released by the low 
endosomal pH, to the apical membrane. A definite pathogenetic concept, however, is still 
lacking.  
4.4 Consequences of ClC-5 dysfunction for the α-intercalated cells 
As the acidifying capacity after ammonium chloride loading is normal in the initial phase of 
Dent’s disease, normal H+ ATPase has to be present at the apical surface of the  
┙-intercalated cells. Carr et al. (2006) demonstrated in a collecting duct cell line, in which 
ClC-5 was disrupted, a marked increase in annexin A2, a crystal-binding molecule at the 
plasma membrane. This leads to an accumulation of crystal binding molecules at this site 
and might underlie nephrocalcinosis in patients with Dent’s disease. Interestingly, 
aquaporin 6 co-localizes with H+ ATPase in ┙-intercalated cells and functions as an anion 
channel, facilitating Cl- transport (Yasui et al., 1999). The physiological role of aquaporin 6 
and its relation to ClC-5 in ┙-intercalated cells remains to be established.  
4.5 Role of OCRL in endosomal trafficking 
Detailed description of the cellular phenotype caused by OCRL mutations is beyond the 
scope of this chapter. OCRL protein belongs to a type II polyphosphate 5-phosphatases and 
is ubiquitously expressed in the Trans-Golgi Network (TGN), endosomes and plasma 
membrane. OCRL interacts with a broad range of small Rab GTPases, a family of proteins, 
which together with phosphatidylinositols regulate cellular vesicle trafficking (Vicinanza et 
al., 2008). Other OCRL interactors include clathrin and adaptor proteins AP1 and AP2. Some 
mutations detected in patients with Lowe syndrome disturb interaction between OCRL-
protein and several Rab GTPases (Hou et al., 2011), however, functional consequences of the 
other mutations found in Lowe syndrome or in Dent 2 disease are unknown and a 
mechanistic explanation of differences between the two phenotypes remains to be clarified.  
5. Treatment of Dent’s disease 
At this moment there is no curative treatment of Dent’s disease. Supportive therapy is 
focused on preventing renal stone formation and slowing down the deterioration of renal 
function. Increased fluid intake and administration of hydrochlorothiazide (HCT) decrease 
urinary calcium concentrations (Raja et al., 2002), however, hypovolemia and hypokalemia 
can complicate thiazide treatment (Blanchard et al., 2008). High citrate diet has a positive 
effect on renal stone formation in the ClC-5 knockout mice (Chebotaru et al., 2005), but its 
efficiency has not been proven in humans. Inhibition of the renin-angiotensin-aldosterone 
system (RAAS) might be of potential benefit by reducing proteinuria, but its effect in Dent’s 
disease patients has not been studied. Treatment of rickets with vitamin D and phosphate 
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supplementation should be performed with caution as it can enhance hypercalciuria and 
nephrocalcinosis.  
Smith et al. (2009) reported that some ClC-5 missense mutants are retained in the 
endoplasmatic reticulum. The authors suggested that the export of mutant channels might 
be improved by exposure to chaperones improving forward trafficking by allosteric means. 
Therefore, the identification of allosteric modulators, specific for ClC-5, may provide a 
therapy for Dent 1 disease at least caused by this type of mutation. 
6. Conclusions 
Dent’s disease is a rare X-linked disorder characterized by various degrees of proximal 
tubular dysfunction, nephrocalcinosis and nephrolithiasis. The disease leads to progressive 
loss of kidney function and causes end stage renal failure (ESRD) mostly in the 3rd to 4th 
decades of life. Dent’s disease mostly affects males, however, female carries can develop 
mild proximal tubular dysfunction and more rarely nephrolithiasis. Approximately 60% of 
all Dent’s patients (i.e. Dent 1 patients) have inactivating mutations in the CLCN5 gene 
encoding the electrogenic Cl-/H+ exchanger ClC-5, which is extensively expressed on the 
early endosomes in renal PT and is involved in the receptor-mediated endocytosis.  
About 15% of Dent’s patients have mutations in the OCRL gene and are classified as having 
Dent 2 disease. OCRL gene, encoding phosphatidyl-inositol phosphate 5-phosphatase, is 
known to cause Lowe syndrome, a severe form of X-linked mental retardation associated 
with proximal tubular dysfunction and congenital cataract.  
Studying the pathogenesis of Dent’s has elucidated the crucial role of the ClC-5 protein in 
endosomal acidification required for the progression along the endocytotic machinery. 
Recent studies demonstrated that ClC-5 functions as a 2Cl-/H+ exchanger, which is directly 
involved in the acidification of early endosomes.  
Treatment of patients with Dent’s disease is supportive and focused on preventing renal 
stone formation and slowing down the deterioration of their renal function. Increased fluid 
intake and cautious administration of HCT can decrease urinary calcium concentrations. 
Inhibition of RAAS might be of potential benefit by reducing proteinuria.  
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